Elicio Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Elicio Therapeutics, Inc. (ELTX) reported Increase Decrease In Operating Lease Liability of -$492.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- Elicio Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$252.00K.
- Elicio Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$240.00K.
- Elicio Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$232.00K.
- Elicio Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$228.00K.
- Elicio Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$901.00K.
- Elicio Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$911.00K.
- Elicio Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$825.00K.
- Elicio Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$535.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 3 month as first filed | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 6 month as first filed | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 9 month as first filed | Increase Decrease In Operating Lease Liability 12 month | Increase Decrease In Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$252.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$492.00K 10-Q · filed 2026-08-13 | -$724.00K derived: sum of 3 quarters · filed 2026-08-13 | -$952.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$240.00K 10-Q · filed 2026-05-11 | -$472.00K derived: sum of 2 quarters · filed 2026-05-11 | -$700.00K derived: sum of 3 quarters · filed 2026-05-11 | -$926.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$232.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$460.00K derived: sum of 2 quarters · filed 2026-03-12 | -$686.00K derived: sum of 3 quarters · filed 2026-08-13 | -$901.00K 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$454.00K derived: sum of 2 quarters · filed 2026-08-13 | -$669.00K 10-Q · filed 2025-11-13 | -$878.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$441.00K 10-Q · filed 2026-08-13 | -$650.00K derived: sum of 3 quarters · filed 2026-08-13 | -$854.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$215.00K 10-Q · filed 2026-05-11 | -$424.00K derived: sum of 2 quarters · filed 2026-05-11 | -$628.00K derived: sum of 3 quarters · filed 2026-05-11 | -$882.00K derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$413.00K derived: sum of 2 quarters · filed 2026-03-12 | -$667.00K derived: sum of 3 quarters · filed 2026-03-12 | -$911.00K 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$204.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$458.00K derived: sum of 2 quarters · filed 2025-11-13 | -$702.00K 10-Q · filed 2025-11-13 | -$939.00K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$254.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$498.00K 10-Q · filed 2025-08-07 | -$735.00K derived: sum of 3 quarters · filed 2025-08-07 | -$986.00K derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$244.00K 10-Q · filed 2025-05-13 | -$481.00K derived: sum of 2 quarters · filed 2025-05-13 | -$732.00K derived: sum of 3 quarters · filed 2025-05-13 | -$906.00K derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$488.00K derived: sum of 2 quarters · filed 2025-03-31 | -$662.00K derived: sum of 3 quarters · filed 2025-03-31 | -$825.00K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$251.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$425.00K derived: sum of 2 quarters · filed 2024-11-13 | -$588.00K 10-Q · filed 2024-11-13 | -$745.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$337.00K 10-Q · filed 2024-08-13 | -$494.00K derived: sum of 3 quarters · filed 2024-08-13 | -$648.00K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$163.00K 10-Q · filed 2024-05-15 | -$55.00K 10-Q · filed 2023-05-10 | -$320.00K derived: sum of 2 quarters · filed 2024-05-15 | -$474.00K derived: sum of 3 quarters · filed 2024-05-15 | -$483.00K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$311.00K derived: sum of 2 quarters · filed 2024-03-29 | -$320.00K derived: sum of 3 quarters · filed 2024-03-29 | -$535.00K 10-K · filed 2024-03-29 | -$894.00K 10-K · filed 2023-03-17 | |||
| 2022-09-30 | -$154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$163.00K derived: sum of 2 quarters · filed 2023-11-13 | -$378.00K 10-Q · filed 2023-11-13 | -$663.00K 10-Q · filed 2022-11-14 | -$585.00K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$224.00K 10-Q · filed 2023-08-14 | -$436.00K 10-Q · filed 2022-08-15 | -$431.00K derived: sum of 3 quarters · filed 2023-08-14 | -$634.00K derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$215.00K 10-Q · filed 2023-05-10 | -$422.00K derived: sum of 2 quarters · filed 2023-05-10 | -$625.00K derived: sum of 3 quarters · filed 2023-05-10 | -$782.00K derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$410.00K derived: sum of 2 quarters · filed 2023-03-17 | -$567.00K derived: sum of 3 quarters · filed 2023-03-17 | -$713.00K 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | -$203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$360.00K derived: sum of 2 quarters · filed 2022-11-14 | -$506.00K 10-Q · filed 2022-11-14 | -$629.00K derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$303.00K 10-Q · filed 2022-08-15 | -$426.00K derived: sum of 3 quarters · filed 2022-08-15 | -$579.00K derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | -$146.00K 10-Q · filed 2022-05-16 | -$269.00K derived: sum of 2 quarters · filed 2022-05-16 | -$422.00K derived: sum of 3 quarters · filed 2022-05-16 | -$554.00K derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | -$123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$276.00K derived: sum of 2 quarters · filed 2022-03-30 | -$408.00K derived: sum of 3 quarters · filed 2022-03-30 | -$560.00K 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | -$153.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$285.00K derived: sum of 2 quarters · filed 2021-11-12 | -$437.00K 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | -$132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$284.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$152.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |